Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.

RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.